Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Du

Patients treated with dual immunotherapy-based combination demonstrate sustained clinical benefits after four years vs. chemotherapy alone, with magnitude of benefit more pronounced amongst patient... | June 4, 2023

Related Keywords

United States , Japan , China , Taiwan , South Korea , American , Bristol Myers Squibb , Davidp Carbone , Drug Administration , Company Opdivo , Instagram , Thoracic Oncology Center , Youtube , European Union , Solove Research Institute , Ono Pharmaceutical Co , American Society Of Clinical Oncology , Facebook , Ohio State University Comprehensive Cancer Center , Twitter , Linkedin , Hazard Ratio , Confidence Interval , Clinical Oncology , Annual Meeting , James Cancer Hospital , Solove Research , Myers Squibb , Better Future , Fatal Immune Mediated Adverse , Full Prescribing Information , Allogeneic Hematopoietic Stem Cell , Multiple Myeloma , Thalidomide Analogue , Prescribing Information , Ono Pharmaceutical , Statement Regarding Forward Looking , Bristol Myers Squibb Company Stock Exchange , News , Information , Press Release , Patients , Reated , Ith , Ual , Combination , Emonstrate , Sustained , Linical , Benefits , After , Four , Tears , Chemotherapy , Magnitude , F , Benefit , More , Pronounced , Mongst Bmy Us1101221083 ,